

Global Care Capital and Shanghai Biotechnology Devices (Virax Biolabs) reach a Settlement and Release Agreement

*NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES*

VANCOUVER, British Columbia, January 29th, 2021 -- **Global Care Capital Inc.** (CSE: **HLTH**, OTC: **RSCZF**, FRANKFURT: **L6V1**) (the “**Company**” or “**Global Care**”) a global investment company which engages in early stage investment opportunities in private and public companies, announces that a Settlement and Release Agreement has been signed between its portfolio company, ViraxClear and its joint venture partner, Shanghai Biotechnology Devices (“**SBD**”), which trades as Virax Biolabs thereby reducing Global Care’s equity in SBD to 12.5%.

James Foster, CEO of Virax Biolabs, states; “This Agreement allows both Parties to pursue exciting opportunities as we advance in different directions.”

Alex Somjen, President & CEO of Global Care Capital stated “We are pleased to reach a conclusion amicably with Virax Biolabs. We have been happy to work with the Virax Biolabs team and wish them the best as we continue as minority shareholders.”

The Agreement

The Parties have agreed to mutually terminate their prior Investment Agreement, and to release one another from any and all claims, and interests arising thereunder, and as evidence of their settlement in this regard have entered into this Agreement. Global Care's equity position in SBD has been reduced from 50% to 12.5%.

Virax Biolabs (Shanghai Biotechnology Devices Limited)

Virax Biolabs operate both the ViraxCare and ViraxClear brands. ViraxCare aims to minimise the risks of COVID-19 and other respiratory diseases on behalf of major corporations and SMEs throughout the world through the provision of innovative, high-quality MedTech solutions at competitive prices. ViraxCare has also developed AI-powered Sanitising Bots, Sanitising Arches and Tunnels and a smart wearable device that helps employees to social distance. ViraxClear offers a range of Rapid COVID-19 Tests and is launching a new Neutralising Antibody Test, which can detect immune responses to vaccines. Virax Biolabs soon to be launched ViraxImmune platform utilises T-Cell blood Testing to build a full immunological profile to allow people to assess how their bodies are likely to respond to viral threats and advise how best to improve this.

About Global Care

Global Care Capital is a global investment company which specializes in providing early stage financing to private and public companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining positions in early stage investment opportunities that adequately reflect the risk profile.

www.globalcarecapital.com

SHANGHAI BIOTECHNOLOGY DEVICES LIMITED.:

Company Contact

James Foster, CEO

info@viraxcare.com

GLOBAL CARE CAPITAL INC.:

Company Contact:

Company Contact:

Alex Somjen, President & CEO

604-687-2038

info@globalcarecapital.com

The CSE does not accept responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING INFORMATION DISCLAIMER

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com